Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing

Citations Over TimeTop 1% of 2014 papers

Abstract

Conjugation of small interfering RNA (siRNA) to an asialoglycoprotein receptor ligand derived from N-acetylgalactosamine (GalNAc) facilitates targeted delivery of the siRNA to hepatocytes in vitro and in vivo. The ligands derived from GalNAc are compatible with solid-phase oligonucleotide synthesis and deprotection conditions, with synthesis yields comparable to those of standard oligonucleotides. Subcutaneous (SC) administration of siRNA-GalNAc conjugates resulted in robust RNAi-mediated gene silencing in liver. Refinement of the siRNA chemistry achieved a 5-fold improvement in efficacy over the parent design in vivo with a median effective dose (ED50) of 1 mg/kg following a single dose. This enabled the SC administration of siRNA-GalNAc conjugates at therapeutically relevant doses and, importantly, at dose volumes of ≤1 mL. Chronic weekly dosing resulted in sustained dose-dependent gene silencing for over 9 months with no adverse effects in rodents. The optimally chemically modified siRNA-GalNAc conjugates are hepatotropic and long-acting and have the potential to treat a wide range of diseases involving liver-expressed genes.

Related Papers

• → Novel Targeted Liposomes Deliver siRNA to Hepatocellular Carcinoma Cells in vitro(2012)14 cited
• → Autoantibodies to Human Asialoglycoprotein Receptor in Autoimmune–Type Chronic Hepatitis(1990)113 cited
• → Short Interfering RNA (siRNA)—Mediated RNA Interference (RNAi) in Human Cells(2003)82 cited
• → Can siRNA Technology Provide the Tools for Gene Therapy of the Future?(2006)34 cited
• [A preview of the practical application of hybrid artificial liver].(1991)